CDMOs offering Lentiviral Vector Manufacturing with Vaccine
Lentiviral Vector Manufacturing combined with Vaccine is a common shortlist filter for sponsors evaluating CDMO partners. This explore page lists organizations that publicly map to both dimensions, so you can move from taxonomy browsing to a tighter candidate set without rebuilding filters from scratch.
Profiles here are fit-first: open each listing for scope, geography, regulatory posture, and provenance-backed facts. The directory does not rank these rows as a single "best" answer — use them to assemble a right-sized outreach list for your program stage and quality bar.
When you need adjacent criteria (indications, claim status, or cross-category search), continue to the main search experience and layer filters on top of this service × modality starting point.
Auto-generated by BioBM Editorial AI.
Matching companies
- Aldevron
Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.
- Creative Biogene
Creative Biogene provides viral vector manufacturing, cell line development, and RNA therapeutic platforms including AAV, lentivirus, adenovirus production, circular RNA synthesis, and lipid nanoparticle formulation for gene therapy and vaccine applications.
- Oxford Biomedica
Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- WuXi Advanced Therapies
Cell & gene therapy CDMO offering discovery, process development, analytical development, cell banking, clinical and commercial manufacturing, plus biosafety testing for biologics, mAbs, vaccines, and CGT developers.
Related: Lentiviral Vector Manufacturing service page · Vaccine modality page
Markdown mirror: /explore/svc_lentivirus_manufacturing/mod_vaccine.md